Search

Author/Creator Laffi, G.

3. Interferon‐free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis. Issue 4 (28th June 2018)

Authors:
Gragnani, L.; Cerretelli, G.; Lorini, S.; Steidl, C.; Giovannelli, A.; Monti, M.; Petraccia, L.; Sadalla, S.; Urraro, T.; Caini, P.; Xheka, A.; Simone, A.; Arena, U.; Matucci‐Cerinic, M.; Vergani, D.; Laffi, G.; Zignego, A. L.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 48:Issue 4(2018)
Page Start:
440
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Long-term albumin therapy is not futile in patients with cirrhosis and uncomplicated ascites not normalizing on-treatment serum albumin concentration. (February 2020)

Authors:
Tufoni, M.; Caraceni, P.; Zaccherini, G.; Riggio, O.; Angeli, P.; Alessandria, C.; Neri, S.; Foschi, F.G.; Levantesi, F.; Airoldi, A.; Simone, L.; Svegliati-Baroni, G.; Fagiuoli, S.; Laffi, G.; Cozzolongo, R.; Di Marco, V.; Sangiovanni, V.; Morisco, F.; Toniutto, P.; Tortora, A.
Journal:
Digestive and liver disease
Issue:
Volume 52(2020)Supplement 1
Page Start:
e57
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: The interim analysis of the ANSWER study. (15th February 2015)

Authors:
Bernardi, M.; Riggio, O.; Angeli, P.; Alessandria, C.; Neri, S.; Foschi, F.G.; Levantesi, F.; Boccia, S.; Airoldi, A.; Fagiuoli, S.; Svegliati-Baroni, G.; Laffi, G.; Cozzolongo, R.; Butera, G.; Sangiovanni, V.; Toniutto, P.; Zocco, M.A.; De Marco, R.; Morisco, F.; De Leonardis, F.
Journal:
Digestive and liver disease
Issue:
Volume 47(2015)Supplement 1
Page Start:
e6
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. OP0186 Etiological therapy in HCV-related mixed cryoglobulinemia syndrome: The role of IL28B genotype as predictor of response. (23rd January 2014)

Authors:
Urraro, T.; Piluso, A.; Giannini, C.; Fognani, E.; Gragnani, L.; Caini, P.; Monti, M.; Triboli, E.; Pellegrini, E.; Petrarca, A.; Ranieri, J.; Laffi, G.; Zignego, A.L.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 71(2012)Supplement 3
Page Start:
117
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Time-varying mHAP III is the most accurate score in predicting survival in patients with hepatocellular carcinoma (HCC) undergoing trans-arterial chemoembolization (TACE). (February 2019)

Authors:
Campani, C.; Vitale, A.; Dragoni, G.; Aburas, S.; Arena, U.; Laffi, G.; Cillo, U.; Giannini, E.G.; Trevisani, F.; Marra, F.
Journal:
Digestive and liver disease
Issue:
Volume 51(2019)Supplement 1
Page Start:
e6
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Value of IL28B genotyping in patients with HCV‐related mixed cryoglobulinemia: results of a large, prospective study. Issue 4 (4th December 2012)

Authors:
Piluso, A.; Giannini, C.; Fognani, E.; Gragnani, L.; Caini, P.; Monti, M.; Petrarca, A.; Ranieri, J.; Urraro, T.; Triboli, E.; Laffi, G.; Zignego, A. L.
Journal:
Journal of viral hepatitis
Issue:
Volume 20:Issue 4(2013)
Page Start:
e107
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗